Supernus Pharmaceuticals Inc. reported total revenues of $192.1 million for the third quarter of 2025, a 9% increase compared to the same period in 2024. Combined revenues from the company's four growth products rose 52% to $149.2 million, driven by higher net sales of Qelbree and GOCOVRI, as well as the addition of sales from ZURZUVAE and ONAPGO. Net product sales for Qelbree reached $81.4 million, an increase of 31% from $62.4 million in the third quarter of 2024, while GOCOVRI sales were $40.8 million, up 15% from $35.6 million. The company completed the acquisition of Sage Therapeutics on July 31, 2025. Operating losses for the quarter were $60.2 million, impacted by higher selling, general and administrative expenses, including $70.0 million in acquisition-related costs. Adjusted operating earnings (non-GAAP) for the quarter were $41.9 million, compared to $67.7 million in the same period the previous year. Cash, cash equivalents, and current marketable securities totaled approximately $281.2 million as of September 30, 2025.